Escape mechanisms from antibody therapy to lymphoma cells

Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation

Takumi Sugimoto, Akihiro Tomita, Junji Hiraga, Kazuyuki Shimada, Hitoshi Kiyoi, Tomohiro Kinoshita, Tomoki Naoe

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Although rituximab is a critical monoclonal antibody therapy for CD20-positive B-cell lymphomas, rituximab resistance showing a CD20-negative phenotypic change has been a considerable clinical problem. Here we demonstrate that CD20 mRNA and protein expression is repressed by recruitment of a histone deacetylase protein complex to the MS4A1 (CD20) gene promoter in CD20-negative transformed cells after treatment with rituximab. CD20 mRNA and protein expression were stimulated by decitabine (5-Aza-dC) in CD20-negative transformed cells, and was enhanced by trichostation A (TSA). Immunoblotting indicated that DNMT1 expression was first downregulated 1 day after treatment with 5-Aza-dC, but IRF4 and Pu.1, the transcriptional regulators of MS4A1, were still expressed with or without 5-Aza-dC. Interestingly, CpG methylation of the MS4A1 promoter was not observed in CD20-negative transformed cells without 5-Aza-dC. A chromatin immunoprecipitation (ChIP) assay indicated that the Sin3A-HDAC1 co-repressor complex was recruited to the promoter and dissociated from the promoter with 5-Aza-dC and TSA, resulting in histone acetylation. Under these conditions, IRF4 and Pu.1 were continually recruited to the promoter with or without 5-Aza-dC and TSA. These results suggest that recruitment of the Sin3A-HDAC1 complex is related to downregulation of CD20 expression in CD20-negative B-cells after treatment with rituximab.

Original languageEnglish
Pages (from-to)48-53
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume390
Issue number1
DOIs
Publication statusPublished - 04-12-2009
Externally publishedYes

Fingerprint

DNA Methylation
Lymphoma
Down-Regulation
Messenger RNA
Antibodies
decitabine
Cells
Acetylation
Co-Repressor Proteins
Proteins
Methylation
Histone Deacetylases
Chromatin Immunoprecipitation
B-Cell Lymphoma
Therapeutics
Immunoblotting
Histones
Chromatin
Assays
B-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Sugimoto, Takumi ; Tomita, Akihiro ; Hiraga, Junji ; Shimada, Kazuyuki ; Kiyoi, Hitoshi ; Kinoshita, Tomohiro ; Naoe, Tomoki. / Escape mechanisms from antibody therapy to lymphoma cells : Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. In: Biochemical and Biophysical Research Communications. 2009 ; Vol. 390, No. 1. pp. 48-53.
@article{5d7cfb4880fa49ad98ca196f40c9b807,
title = "Escape mechanisms from antibody therapy to lymphoma cells: Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation",
abstract = "Although rituximab is a critical monoclonal antibody therapy for CD20-positive B-cell lymphomas, rituximab resistance showing a CD20-negative phenotypic change has been a considerable clinical problem. Here we demonstrate that CD20 mRNA and protein expression is repressed by recruitment of a histone deacetylase protein complex to the MS4A1 (CD20) gene promoter in CD20-negative transformed cells after treatment with rituximab. CD20 mRNA and protein expression were stimulated by decitabine (5-Aza-dC) in CD20-negative transformed cells, and was enhanced by trichostation A (TSA). Immunoblotting indicated that DNMT1 expression was first downregulated 1 day after treatment with 5-Aza-dC, but IRF4 and Pu.1, the transcriptional regulators of MS4A1, were still expressed with or without 5-Aza-dC. Interestingly, CpG methylation of the MS4A1 promoter was not observed in CD20-negative transformed cells without 5-Aza-dC. A chromatin immunoprecipitation (ChIP) assay indicated that the Sin3A-HDAC1 co-repressor complex was recruited to the promoter and dissociated from the promoter with 5-Aza-dC and TSA, resulting in histone acetylation. Under these conditions, IRF4 and Pu.1 were continually recruited to the promoter with or without 5-Aza-dC and TSA. These results suggest that recruitment of the Sin3A-HDAC1 complex is related to downregulation of CD20 expression in CD20-negative B-cells after treatment with rituximab.",
author = "Takumi Sugimoto and Akihiro Tomita and Junji Hiraga and Kazuyuki Shimada and Hitoshi Kiyoi and Tomohiro Kinoshita and Tomoki Naoe",
year = "2009",
month = "12",
day = "4",
doi = "10.1016/j.bbrc.2009.09.059",
language = "English",
volume = "390",
pages = "48--53",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

Escape mechanisms from antibody therapy to lymphoma cells : Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. / Sugimoto, Takumi; Tomita, Akihiro; Hiraga, Junji; Shimada, Kazuyuki; Kiyoi, Hitoshi; Kinoshita, Tomohiro; Naoe, Tomoki.

In: Biochemical and Biophysical Research Communications, Vol. 390, No. 1, 04.12.2009, p. 48-53.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Escape mechanisms from antibody therapy to lymphoma cells

T2 - Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation

AU - Sugimoto, Takumi

AU - Tomita, Akihiro

AU - Hiraga, Junji

AU - Shimada, Kazuyuki

AU - Kiyoi, Hitoshi

AU - Kinoshita, Tomohiro

AU - Naoe, Tomoki

PY - 2009/12/4

Y1 - 2009/12/4

N2 - Although rituximab is a critical monoclonal antibody therapy for CD20-positive B-cell lymphomas, rituximab resistance showing a CD20-negative phenotypic change has been a considerable clinical problem. Here we demonstrate that CD20 mRNA and protein expression is repressed by recruitment of a histone deacetylase protein complex to the MS4A1 (CD20) gene promoter in CD20-negative transformed cells after treatment with rituximab. CD20 mRNA and protein expression were stimulated by decitabine (5-Aza-dC) in CD20-negative transformed cells, and was enhanced by trichostation A (TSA). Immunoblotting indicated that DNMT1 expression was first downregulated 1 day after treatment with 5-Aza-dC, but IRF4 and Pu.1, the transcriptional regulators of MS4A1, were still expressed with or without 5-Aza-dC. Interestingly, CpG methylation of the MS4A1 promoter was not observed in CD20-negative transformed cells without 5-Aza-dC. A chromatin immunoprecipitation (ChIP) assay indicated that the Sin3A-HDAC1 co-repressor complex was recruited to the promoter and dissociated from the promoter with 5-Aza-dC and TSA, resulting in histone acetylation. Under these conditions, IRF4 and Pu.1 were continually recruited to the promoter with or without 5-Aza-dC and TSA. These results suggest that recruitment of the Sin3A-HDAC1 complex is related to downregulation of CD20 expression in CD20-negative B-cells after treatment with rituximab.

AB - Although rituximab is a critical monoclonal antibody therapy for CD20-positive B-cell lymphomas, rituximab resistance showing a CD20-negative phenotypic change has been a considerable clinical problem. Here we demonstrate that CD20 mRNA and protein expression is repressed by recruitment of a histone deacetylase protein complex to the MS4A1 (CD20) gene promoter in CD20-negative transformed cells after treatment with rituximab. CD20 mRNA and protein expression were stimulated by decitabine (5-Aza-dC) in CD20-negative transformed cells, and was enhanced by trichostation A (TSA). Immunoblotting indicated that DNMT1 expression was first downregulated 1 day after treatment with 5-Aza-dC, but IRF4 and Pu.1, the transcriptional regulators of MS4A1, were still expressed with or without 5-Aza-dC. Interestingly, CpG methylation of the MS4A1 promoter was not observed in CD20-negative transformed cells without 5-Aza-dC. A chromatin immunoprecipitation (ChIP) assay indicated that the Sin3A-HDAC1 co-repressor complex was recruited to the promoter and dissociated from the promoter with 5-Aza-dC and TSA, resulting in histone acetylation. Under these conditions, IRF4 and Pu.1 were continually recruited to the promoter with or without 5-Aza-dC and TSA. These results suggest that recruitment of the Sin3A-HDAC1 complex is related to downregulation of CD20 expression in CD20-negative B-cells after treatment with rituximab.

UR - http://www.scopus.com/inward/record.url?scp=70349958004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349958004&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2009.09.059

DO - 10.1016/j.bbrc.2009.09.059

M3 - Article

VL - 390

SP - 48

EP - 53

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -